SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27416-27426

  Deng, Gang ^a   Zhu, Lei ^a   Huang, Feizhou ^a   Nie, Wanpin ^a   Huang, Wei ^a   Xu, Hongbo ^a   Zheng, Shaopeng ^a   Yi, Zhongjie ^a   Wan, Tao ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Intrahepatic cholangiocarcinoma; Invasion; Migration; Proliferation; SALL4

Indexed keywords

CA 19-9 ANTIGEN; CELL MARKER; KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; SAL LIKE PROTEIN 4; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; CARBOHYDRATE ANTIGEN 199, HUMAN; SALL4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRATION INHIBITION; NERVE INVASION; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; UPREGULATION; VASCULAR INVASION; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; METASTASIS; TREATMENT OUTCOME; TUMOR CELL LINE; WOUND HEALING;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84944463120     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4862     Document Type: Article

References (27)

1. Sanada Y, Kawashita Y, Okada S, Azuma T, Matsuo S. Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma. World J Gastrointest Pathophysiol. 2014; 5:188-199.
2. Andersen JB. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014.
3. Baheti AD, Tirumani SH, Rosenthal MH, Shinagare AB, Ramaiya NH. Diagnosis and management of intrahepatic cholangiocarcinoma: A comprehensive update for the radiologist. Clin Radiol. 2014.
4. Ayuso JR, Pages M, Darnell A. Imaging bile duct tumors: staging. Abdom Imaging. 2013; 38:1071-1081.
5. Settakorn J, Kaewpila N, Burns GF, Leong AS. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol. 2005; 58:1249-1254.
6. Jain D. Sal-like protein 4: an epithelial and germ cell marker. Hum Pathol. 2013; 44:1453.
7. Osada M, Aishima S, Hirahashi M, Takizawa N, Takahashi S, Nakamura K, Tanaka M, Maehara Y, Takayanagi R, Oda Y Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma. Hum Pathol. 2014; 45:1243-1250.
8. Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014; 3:71-84.
9. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013; 57:1469-1483.
10. Shikauchi Y, Saiura A, Kubo T, Niwa Y, Yamamoto J, Murase Y, Yoshikawa H. SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. Mol Cell Biol. 2009; 29:1944-1958.
11. Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, Nomura Y, Yoshida M, Oishi N, Ikeda H, Honda M, Kaneko S. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol. 2014; 60:127-134.
12. Han SX, Wang JL, Guo XJ, He CC, Ying X, Ma JL, Zhang YY, Zhao Q, Zhu Q. Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma. J Immunol Res. 2014; 2014:262385.
13. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med. 2013; 368:2266-2276.
14. Wang F, Liu A, Peng Y, Rakheja D, Wei L, Xue D, Allan RW, Molberg KH, Li J, Cao D. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol. 2009; 33:1529-1539.
15. Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol. 2014; 38:966-972.
16. Gonzalez-Roibon N, Katz B, Chaux A, Sharma R, Munari E, Faraj SF, Illei PB, Torbenson M, Netto GJ. Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. Hum Pathol. 2013; 44:1293-1299.
17. Zhang J, Tam WL, Tong GQ, Wu Q, Chan HY, Soh BS, Lou Y, Yang J, Ma Y, Chai L, Ng HH, Lufkin T, Robson P, Lim B. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol. 2006; 8:1114-1123.
18. Elling U, Klasen C, Eisenberger T, Anlag K, Treier M. Murine inner cell mass-derived lineages depend on Sall4 function. Proc Natl Acad Sci U S A. 2006; 103:16319-16324.
19. Yang J, Gao C, Chai L, Ma Y. A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One. 2010; 5:e10766.
20. Milanovich S, Peterson J, Allred J, Stelloh C, Rajasekaran K, Fisher J, Duncan S, Malarkannan S, Rao S. Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol. 2015; 43:53-64.e1-e8.
21. Ardalan Khales S, Abbaszadegan MR, Abdollahi A, Raeisossadati R, Tousi MF, Forghanifard MM. SALL4 as a new biomarker for early colorectal cancers. J Cancer Res Clin Oncol. 2015; 141:229-235.
22. Forghanifard MM, Ardalan Khales S, Javdani-Mallak A, Rad A, Farshchian M, Abbaszadegan MR. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma. Med Oncol. 2014; 31:922.
23. Wang P, Zhang JD, Wu F, Ye X, Sharon D, Hitt M, McMullen TP, Hegazy SA, Gelebart P, Yang J, Ma Y, Lai R. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012; 24:1955-1963.
24. Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang M, Zhang X, Yang T, Cai J, Yan Y, Mao F, Zhu W, Shao Q, Qian H, Xu W. SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene. 2013.
25. Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011; 26:965-970.
26. Itou J, Matsumoto Y, Yoshikawa K, Toi M. Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer. FEBS Lett. 2013; 587:3115-3121.
27. Li A, Jiao Y, Yong KJ, Wang F, Gao C, Yan B, Srivastava S, Lim GS, Tang P, Yang H, Tenen DG, Chai L. SALL4 is a new target in endometrial cancer. Oncogene. 2015; 34:63-72.